Use of Virtual Reality as a Tool for Cognitive Remediation in Elderly Depressed Patients

Every patient diagnosed with depression receives psychotropic treatment comprising one or more antidepressants, possibly combined with one or more thymoregulators (e.g. bipolar patients), one or more anxiolytics and/or a hypnotic. The elderly depressive patient is also treated with supportive psychotherapy and/or group therapy at the day hospital. The trial proposes an additional tool, virtual reality, aimed at improving the cognitive abilities, particularly executive abilities, of the elderly depressive subject, thereby helping to maintain his or her functional abilities, i.e. his or her ability to stay as autonomous as possible at home and maintain a good quality of life. In fact, cognitive disorders associated with depression do not respond to antidepressant medication, if at all. It therefore seems important to optimize the treatment of depression in the elderly subject by adding a cognitive target. The investigators's project is to offer patients the opportunity to live in a virtual kitchen, where they can carry out everyday tasks. The scenario for the VR sessions has been designed in collaboration with, the principal investigator at CHU and his team, and the members of B COM and HDG involved in the study. Particular attention is paid to the fact that this scenario is intended for an elderly patient population, so as to prevent as far as possible the occurrence of cybermalaise The patient will be asked to arrange food shopping appropriately, differentiating between perishable and non-perishable foodstuffs and non-food items, or to prepare cooking recipes. Virtual reality has the advantage of being able to offer ecological, configurable activities, targeting precise tasks that call on executive functions such as initiative, anticipation and planning, mental flexibility and inhibition. Patients will undergo 12 VR sessions at a rate of 2 sessions per week for 6 weeks.

Inclusion criteria

• Patients aged 70 or over;
• Patient with a characterized depressive episode as assessed by the GDS (Score > 13 at inclusion);
• Patient with a minimum MMS score of 23/30 at inclusion;
• Patient affiliated to or benefiting from a social security scheme;
• Patient having received information on the protocol and having given free, informed and written consent.

Exclusion criteria

• Patients suffering from epilepsy;
• Patients suffering from inner ear disorders;
• Patients with balance disorders or postural instability;
• Patients with swallowing disorders requiring mixed feeding;
• Patients suffering from migraines;
• Patients with major sensory deficits (visual or auditory);
• Patients suffering from eye pathologies or abnormalities, and whose condition strictly contraindicates virtual reality;
• Patients suffering from oculo-motor disorders;
• Patients with sensory-motor deficits affecting the upper limb(s) that prevent them from performing the tasks required during VR sessions;
• Patients suffering from primary neuropathic disorders or secondary to metabolic pathologies;
• Patients suffering from acute psychiatric decompensation that makes it impossible for them to cooperate with the sessions (opposition, agitation, acute delusions, hallucinations, panic attacks);
• Patients with uncontrolled cardiac pathology (angina, heart failure, rhythm disorders, conduction disorders);
• Patients with uncontrolled hypertension (SBP > 140 mmHg and DBP > 90 mmHg in patients with traited hypertension);
• Patients with implanted medical devices (pacemakers, defibrillators, etc.);
• Patients under legal protection (guardianship) or deprived of liberty.
• Patients who do not speak or read French fluently, unable to understand the principle of the study questionnaires and unable to cooperate with the tests.